Aether margin recovers sequentially, but costs still outpace revenue year on year
Revenue momentum improved in Q2FY27, while lower taxes supported profit growth as management flagged elevated raw materials and sharply higher logistics costs.
Filed 30 Oct 2026, 13:41 IST · Aether Industries Ltd (AETHER)
Key takeaways
- Revenue grew 26.22% year on year, but expenses rose 26.55%, trimming operating margin by 0.18 percentage points.
- Net profit increased 26.02% year on year, helped by a 4.17-percentage-point reduction in the tax rate despite interest costs rising 64.40%.
- Operating margin recovered 0.34 percentage points sequentially to 31.81%, but remained below the 34.88% reached in Q3FY26.
Price around the results
Revenue growth returned to a faster sequential pace
Aether Industries reported consolidated revenue growth of 26.22% year on year and 6.33% sequentially in Q2FY27. Operating profit grew 25.49% year on year, slower than revenue because expenses increased 26.55%. The company's 31.81% operating margin was 16.58 percentage points above the 15.23% median for 43 reported Commodities-sector peers.
Margin held up despite raw material and logistics pressure
Sequentially, revenue grew faster than expenses, with growth of 6.33% versus 5.80%, lifting operating margin by 0.34 percentage points. Management said raw material prices remained elevated and logistics costs had increased nearly threefold in the first half of FY27.
Tax benefit cushioned higher finance costs
Net profit grew 26.02% year on year, while profit before tax rose 19.19%, indicating that the lower tax rate supported the reported profit increase. The tax rate fell 4.17 percentage points to 23.18%, partly offsetting a 64.40% increase in interest costs. Other income accounted for 5.74% of pre-tax profit, so it was a contributor but not the main explanation for earnings growth.
Management linked the next phase to CEM, CRAMS and new capacity
Management said CEM and CRAMS together contributed 65.97% of revenue and that the company remained on track for its 70% revenue-mix target. It said additional Baker Hughes products are expected from Q3FY27, while LSM pharmaceutical production is expected to ramp progressively in Q3 and Q4. Management also said total capex for the year is expected at Rs 3,000–3,500 million, including two Magnum production blocks planned for commercialisation by Q3FY27.
No immediate market reaction; recent responses have been evenly split
The results were filed before the market close, but a post-results stock reaction is not yet available. Across the last eight results, the stock rose after four and fell after four, with a median absolute move of 3.29%, making the historical response mixed rather than directionally consistent.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹347 cr | ₹327 cr | +6.33% | +26.22% |
| Other income | ₹5 cr | ₹8 cr | -33.94% | -15.47% |
| Expenses | ₹237 cr | ₹224 cr | +5.80% | +26.55% |
| Operating profit | ₹110 cr | ₹103 cr | +7.47% | +25.49% |
| Operating margin (%) | 31.81% | 31.47% | — | — |
| Interest | ₹5 cr | ₹6 cr | -4.84% | +64.40% |
| Depreciation | ₹22 cr | ₹21 cr | +1.26% | +31.30% |
| Profit before tax | ₹89 cr | ₹83 cr | +6.08% | +19.19% |
| Tax | ₹21 cr | ₹21 cr | -0.87% | +1.03% |
| Net profit | ₹68 cr | ₹63 cr | +8.37% | +26.02% |
| EPS (₹) | ₹5.12 | ₹4.77 | +7.34% | +25.80% |
Operating margin of 31.81% compares with a Commodities sector median of 15.23% across 43 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Commercial sales of semiconductor materials commenced from the pilot plant in October 2026.
Guidance & outlook
- The company is on track to achieve its 70% revenue-mix target for CEM and CRAMS.
- Additional Baker Hughes products are expected to be introduced from Q3 FY27 onwards.
- The company expects the CEM vertical to deliver accelerated growth over the next couple of years.
- LSM pharmaceutical production is expected to ramp progressively during Q3 and Q4 of the current financial year.
- The Oil and Gas sector has a healthy order book for the next six months and a promising CRAMS pipeline.
Expansion
- The new R&D centre will cost approximately ₹1,000 million and include 120 fume hoods and eight technical labs.
- Magnum Site 5 incurred approximately ₹833 million of capex in Q1 FY2027 for two further production blocks.
- The two Magnum production blocks are planned for commercialisation by Q3 FY2027.
- Total capex for the current financial year is expected to be ₹3,000–3,500 million.
New orders
- The Oil and Gas sector had a healthy order book covering the next six months.
New products
- The Magnum site is expected to launch a pharmaceutical product with progressive production ramp-up planned in Q3 and Q4.
- The company began commercialising semiconductor products to customers in Japan through the pilot plant in October 2026.
New initiatives
- The company transitioned its R&D operating framework from 24x6 to 24x7 during the quarter.
- The company commenced work on a silicon project with Dow Chemicals focused on complex chemical engineering design.
- Piping modifications at the Strata site were undertaken to improve operational flexibility and support an expanded product portfolio.
- NMR-based analytical capabilities have broadened the company's work with global majors.
Problems & risks
- The company reported a challenging and volatile macroeconomic environment during the quarter.
- Logistics costs increased nearly threefold during the first half of FY27.
- Raw material prices remained elevated during the period.
- Geopolitical volatility and higher shipping costs led management to stock up on key raw materials.
What to watch
- Whether operating margin remains above 31.81% after the sequential recovery.
- Whether the CEM and CRAMS revenue mix moves from 65.97% towards management's 70% target.
- Progress on the Rs 3,000–3,500 million FY27 capex plan and the two Magnum blocks planned for commercialisation by Q3FY27.